Search Results - "Mook S"

Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): a multicenter observational study.

Authors: Borggreve, A. S. Mook, S. Verheij, M. et al.

Source: BMC Cancer. 10/20/2018, Vol. 18 Issue 1, p1-10. 10p. 1 Diagram.

Determination of surface-active chelating agents.

Authors: Mook, S.

Source: Analytical Chemistry; January 1961, Vol. 33, p150-151, 2p

The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age.

Authors: Mook, S. Schmidt, M. K. Weigelt, B. et al.

Source: Annals of Oncology. Apr2010, Vol. 21 Issue 4, p717-722. 6p. 1 Chart, 3 Graphs.

Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial

Authors: Mook, S. Bonnefoi, H. Pruneri, G. et al.

Source: European Journal of Cancer. May2009, Vol. 45 Issue 7, p1201-1208. 8p.

Association between effectiveness of treatment with curative intent and outcomes of first-line systemic therapy in metachronous metastatic gastroesophageal adenocarcinoma.

Authors: Kamp, D. May, A. M. van Velzen, M. J. M. et al.

Source: British Journal of Cancer. May2026, Vol. 134 Issue 10, p1420-1428. 9p.

OC-0083 MRI guided set-up corrections for esophageal cancer: what margin do we need?

Authors: Boekhoff, M. Mook, S. Borggreve, A. et al.

Source: Radiotherapy & Oncology. 2019 Supplement 1, Vol. 133, pS40-S41. 2p.

Subjects: Esophageal cancer

Successful pregnancy outcome under prolonged ustekinumab treatment in a patient with Crohn's disease and paradoxical psoriasis.

Authors: Galli ‐ Novak, E. Mook, S. ‐ C. Büning, J. et al.

Source: Journal of the European Academy of Dermatology & Venereology. Dec2016, Vol. 30 Issue 12, pe191-e192. 2p.

Impact of endoscopic ultrasonography with fine needle aspiration assessing clinical lymph node staging on radiotherapy treatment planning in esophageal cancer patients.

Authors: Boer, R B den Sanders, M E Meijer, G J et al.

Source: Diseases of the Esophagus. Aug2025, Vol. 38 Issue 4, p1-9. 9p.

SP-0393: Clinical opportunities with MR guided external beam RT.

Authors: Mook, S.

Source: Radiotherapy & Oncology. May2017 Supplement 1, Vol. 123, pS210-S211. 1p.

Online adaptive MR-guided radiotherapy for rectal cancer; feasibility of the workflow on a 1.5T MR-linac: clinical implementation and initial experience.

Authors: Intven, M.P.W. de Mol van Otterloo, S.R. Mook, S. et al.

Source: Radiotherapy & Oncology. Jan2021, Vol. 154, p172-178. 7p.

Subjects: Rectal cancer, Computed tomography, Intensity modulated radiotherapy, Cancer radiotherapy, Patient compliance

Prediction of pneumonia following neoadjuvant chemoradiotherapy in patients with oesophageal cancer.

Authors: Frederiks, M.L. Berbée, M. Schuit, E. et al.

Source: Radiotherapy & Oncology. Jul2026, Vol. 220, pN.PAG-N.PAG. 1p.

Detection of distant interval metastases after neoadjuvant therapy for esophageal cancer with 18 F-FDG PET(/CT): a systematic review and meta-analysis.

Authors: Kroese, T E Goense, L Hillegersberg, R van et al.

Source: Diseases of the Esophagus. Dec2018, Vol. 31 Issue 12, p1-9. 9p.

OC-0714: Feasibility of online adaptive MR-guided radiotherapy for rectal cancer on a 1.5T MR-linac.

Authors: Intven, M. De Mol van Otterloo, S. Mook, S. et al.

Source: Radiotherapy & Oncology. 2020 Supplement 1, Vol. 152, pS403-S404. 2p.

Subjects: Rectal cancer, Cancer radiotherapy

CTV-to-PTV margin assessment for esophageal cancer radiotherapy based on an accumulated dose analysis.

Authors: Boekhoff, M.R. Defize, I.L. Borggreve, A.S. et al.

Source: Radiotherapy & Oncology. Aug2021, Vol. 161, p16-22. 7p.

PO-1385 Clinical outcomes after MR-guided radiotherapy for pancreatic tumors on a 1.5 T MR-linac.

Authors: Eijkelenkamp, H. Grimbergen, G. Daamen, L. et al.

Source: Radiotherapy & Oncology. 2023 Supplement 1, Vol. 182, pS1114-S1116. 3p.

Technical feasibility of magnetic resonance fingerprinting on a 1.5T MRI-linac.

Authors: Bruijnen, T van der Heide, O Intven, M P W et al.

Source: Physics in Medicine & Biology. 11/11/2020, Vol. 65 Issue 22, p1-10. 10p.

123: SEVERE LYMPHOPENIA ACQUIRED DURING CHEMORADIOTHERAPY FOR ESOPHAGEAL CANCER: INCIDENCE AND EXTERNAL VALIDATION OF A PREDICTION MODEL.

Authors: Kroese, T Jairan, J Ruurda, J et al.

Source: Diseases of the Esophagus. 2022 Supplement, Vol. 35, p1-1. 1p.

119: METASTASECTOMY OR STEREOTACTIC BODY RADIATION THERAPY FOR OLIGOMETASTATIC ESOPHAGOGASTRIC CANCER: A NATIONWIDE POPULATION-BASED COHORT STUDY.

Authors: Kroese, T Jorritsma, N Mohammad, N Haj et al.

Source: Diseases of the Esophagus. 2022 Supplement, Vol. 35, p1-1. 1p.

3-Dimensional target coverage assessment for MRI guided esophageal cancer radiotherapy.

Authors: Boekhoff, M.R. Defize, I.L. Borggreve, A.S. et al.

Source: Radiotherapy & Oncology. Jun2020, Vol. 147, p1-7. 7p.

Diagnostic performance of MRI for assessment of response to neoadjuvant chemoradiotherapy in oesophageal cancer.

Authors: Vollenbrock, S. E. Voncken, F. E. M. van Dieren, J. M. et al.

Source: British Journal of Surgery. Apr2019, Vol. 106 Issue 5, p596-605. 10p.